Antibiotic resistance is an emerging global public health
threat spurred by the overuse and misuse of antibiotics. The
majority of the world's annual 5.7 million
antibiotic-treatable deaths occur in low- and middle-income
countries where the mortality burden from treatable
bacterial infections far exceeds the estimated annual
700,000 deaths from antibiotic-resistant infections. In a
new report researcher makes several recommendations
proposing action on R&D (new antibiotics and rapid
diagnostic tests), strengthening regulatory capacities,
encouraging the development and diversification of quality
local manufacturing, exploring innovative funding to reduce
out-of-pocket payments, better treatment guidelines, and
awareness rising. The findings of the report show that even
after the discovery of new antibiotic, regulatory hurdles
and substandard health facilities delay or altogether
prevent widespread market entry and drug availability.
Research shows that of 21 new antibiotics entering markets
between 1999 and 2014, less than five were registered in
most countries in sub-Saharan Africa. Just the mere
existence of an effective antibiotic does not mean that they
are available in countries where they are most needed. Lack
of oversight and regulation in the drug manufacturing and
supply chain leads to poor drug quality and falsified
medicines. Researcher said that 17 percent of the
substandard or falsified medicines reported to the WHO are
antibiotics, and each year, more than 169,000 childhood
pneumonia deaths are caused by falsified antibiotics. Even
when antibiotics are available, patients are often unable to
afford them. Moreover, limited government spending results
in drug shortages in public health facilities which forces
patients to go to private pharmacies or drugstores to buy
medicines that should be provided free. Worldwide, the
irrational use of antibiotics and poor antimicrobial
stewardship lead to treatment failure and propagate the
spread of drug resistance which, in turn, further narrows
the available array of effective antibiotics. Finally,
research and development for new antimicrobials, vaccines,
and diagnostic tests has slowed since the 1960s as
profitable investment in this area is limited by low sales
volumes, short duration of treatment, competition with
established products and cheaper generics, and the
possibility that resistance will rapidly emerge. National
governments, policymakers, pharmaceutical companies, public
and private healthcare institutions, and international
public health bodies all have a role to play in improving
access to antibiotics worldwide. |